Your Health, We Care
Belzutifan is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
FDA，2021.08
Lucius Version of Belzutifan: Dosage and Administration, Indications, PrecautionsIndicationsBelzutif···【more】
Recommended：602025-04-12
Applicable to von Hippel-Lindau (VHL) disease patients requiring treatment for renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastoma, or pancreatic neuroendocri···【more】
Article source：Lucius LaosRelease date：2026-01-05Recommended：13
Lucius Version of Belzutifan: Dosage and Administration, Indications, PrecautionsIndicationsBelzutifan is a hypoxia-inducible factor inhibitor indicated for:Von Hippel-Lindau (VHL)···【more】
Article source：Lucius LaosRelease date：2025-12-04Recommended：60
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
